Pfizer’s $17bn Hospira deal set to close in September after US FTC clearance

By Dan Stanton

- Last updated on GMT

Related tags Pfizer ceo ian European union Pharmacology

US FTC gives Pfizer the thumbs up for Hospira deal
US FTC gives Pfizer the thumbs up for Hospira deal
Pfizer has received the final regulatory clearances to acquire Hospira but the US FTC says it must divests four sterile injectable products.

Pfizer first announced it was buying the Lake Forest, Illinois drug and device maker Hospira in February​ for $17bn (€14bn), and today the Pharma Giant came one step closer after receiving clearance from the US Federal Trade Commission (FTC) on the condition it divests four of its US sterile injectables assets.

The drugs are: Acetylcysteine, used to treat paracetamol overdose, the antibiotic clindamycin, antifungal medication voriconazole, and the chemotherapy agent melphalan.

In the same announcement, Pfizer said Brazil’s Superintendency-General of CADE has also agreed to the merger with no conditions.

“We are pleased to have received these final regulatory approvals for our pending acquisition of Hospira,”​ said Pfizer CEO Ian Read. “We now look forward to combining our two companies and expect the transaction to close in early September.”

The European Commission (EC) has already given the nod​ for the merger to go ahead on the proviso that Pfizer divests various sterile injectable drugs in various member states, as well as Pfizer’s monoclonal antibody candidate infliximab (a biosimilar of J&J’s Remicade a version of which has already been launched across a number of EU states by Hospira).

The Australian Competition and Consumer Commission (ACCC)​ also gave clearance earlier this month.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars